Anti-TIGIT and anti-CD96 antibodies
US11718669B2 · kind B2 · utility
0Cited by
15References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2022 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Aug 10, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.